Inhibrx Biosciences, Inc. (INBX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
the bull case· 3
5
disclosed supplier and customer ties in SEC filings
sec filingsedgar4
of the funds on file reporting a position in INBX
n-portas of Jun 30 '26+15.86%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
8 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized0.35%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '268 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 16 '26 report. Not a forecast, not advice.
High 109.00 at 4:00 am ET, low 106.24 at 9:45 am ET.
Inhibrx Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Of the 6 companies Inhibrx Biosciences, Inc. moves with most closely, none share its SEC classification.
Measured against 149 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
tall tick = annual report · 1 on record
164 managers report a position worth $1.3B between them, and 18 of them hold 80% of it.
INBX (Inhibrx Biosciences, Inc.) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.